(In the Pipeline)
Why do so many preclinical trials fail in rats but succeed in other animals? In his entry, blogger Derek Lowe discusses the possible reasons and solutions for this problem.
Treatment Agreement (The Pharm Voice)
Blogger Gloria Gamat writes about the ISTA Pharmaceuticals' acquisition of Senju Pharmaceuticals' two glaucoma treatments iganidipine and latanoprost.